00:49 , Jan 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Crystallographic studies of CCR9 and CCR2 bound to antagonists could aid the design of allosteric inhibitors of chemokine receptors. Structural analysis of a 315-residue region of a mutant, thermostabilized version of CCR9 complexed...
02:10 , Dec 9, 2016 |  BioCentury  |  Emerging Company Profile

Tumor cell checkpoints

iOmx Therapeutics AG is taking a systematic approach to identifying targets located on tumors that modify T cell activation. The resulting targets are complementary to but independent of PD-1/PD-L1 signaling, which may provide a way...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CC chemokine receptor 9 (CCR9; CDw199)

Gastrointestinal disease INDICATION: Colitis Cell line and mouse studies identified dioxoisoindoline-based CCR9 antagonists that could help treat colitis. Chemical synthesis of dioxoisoindoline analogs and testing in a human cell-based binding assay identified three compounds that bound to...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

Vercirnon: Phase III data

Data from 118 patients with moderately to severely active CD who had completed 12 weeks of treatment prior to study termination in the double-blind, international Phase III SHIELD-4 trial showed that 56% of patients who...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned rights to CCX354, a CC chemokine receptor 1 (CCR1) antagonist that has completed Phase II testing for rheumatoid arthritis (RA). Last year, GSK exercised an option under a 2006...
01:17 , Dec 4, 2013 |  BC Extra  |  Company News

GSK returns remaining ChemoCentryx programs

ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to exercise its option for CCX168, a small molecule complement receptor 5a (C5aR; CD88) inhibitor in the Phase II CLEAR trial for antineutrophil cytoplasmic antibody (ANCA)-associated...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned all rights to vercirnon. In August, the pharma suspended the Phase III program for the CC chemokine receptor 9 ( CCR9) antagonist after the product missed the primary and secondary...
07:00 , Sep 23, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Algeta ASA (OSE:ALGETA) added NOK3.40 to NOK244.40 on Friday after EMA's CHMP recommended approval of Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases....
01:29 , Sep 19, 2013 |  BC Extra  |  Company News

ChemoCentryx regains vercirnon rights from GSK

ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) returned all rights to vercirnon. In August, the pharma suspended the Phase III program for the CC chemokine receptor 9 ( CCR9) antagonist after the product missed...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Vercirnon: Phase III halted

GlaxoSmithKline halted its Phase III program for vercirnon in CD after data from the double-blind, international Phase III SHIELD-1 trial in 608 patients with moderately to severely active CD showed that vercirnon missed the primary...